Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Baxter
McKinsey
Daiichi Sankyo
McKesson
Farmers Insurance
UBS
Colorcon
US Army

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,259,423

« Back to Dashboard

Which drugs does patent 9,259,423 protect, and when does it expire?

Patent 9,259,423 protects LATUDA and is included in one NDA.

Protection for LATUDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seven patent family members in five countries.
Summary for Patent: 9,259,423
Title:Method of treatment for mental disorders
Abstract: The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D.sub.4 receptor agonist.
Inventor(s): Ikeda; Kazuhito (Osaka, JP), Ishiyama; Takeo (Osaka, JP)
Assignee: Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP)
Application Number:13/555,044
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,259,423

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-003 Dec 7, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-001 Oct 28, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-005 Jul 12, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-002 Oct 28, 2010 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,259,423

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2011-033453Feb 18, 2011

Non-Orange Book US Patents Family Members for Patent 9,259,423

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,258,139 Method of treatment for mental disorders ➤ Sign Up
9,827,242 Method of treatment for mental disorders ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cerilliant
Baxter
Cipla
Colorcon
QuintilesIMS
Farmers Insurance
Deloitte
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.